Resources
With our deep research and rich experience, we provide such resources for your better understanding about CCI and Zholion.
-
Q:
Can one instrument test different package sizes?
A:Yes. Different package sizes and shapes can be tested by changing the test chamber, fixture or sample holder.
-
Q:
Can the system test pharmaceutical vials?
A:Yes. Vacuum decay testing can be configured for vials containing powder, lyophilized products or medicinal liquids. A package-specific chamber is normally required.
-
Q:
Which mode should be used for flexible packaging?
A:Pressure decay is generally more suitable for flexible packages that may deform significantly when exposed to vacuum. The final method should be confirmed through package evaluation and feasibility testing.
-
Q:
What is the difference between vacuum decay and pressure decay?
A:Vacuum decay detects leakage by monitoring pressure changes after a vacuum is applied around the package. Pressure decay applies positive pressure and detects leakage by measuring pressure loss.
-
Q:
What is a dual system packaging leak detector?
A:A dual system packaging leak detector integrates two leak testing technologies into one instrument. The MC-DUO(VP) combines vacuum decay and pressure decay testing, allowing it to test a wider range of rigid and flexible packages.
-
Q:
Are traceable calibration certificates available?
A:Yes. Zholion Micropipette Positive Control samples can be supplied with traceable calibration certificates to support quality records, validation studies, and regulatory documentation.
-
Q:
Can Zholion provide custom Micropipette Positive Control Samples?
A:Yes. Zholion can customize pore size, implantation position, according to your CCIT method and validation requirements.
-
Q:
How is Micropipette Positive Control different from Laser Drilling Positive Control?
A:Laser drilling creates a micro-hole directly on the package material, while Micropipette Positive Control uses a controlled capillary glass tube to simulate a defined leakage path. Micropipette samples are especially useful when stable, calculable leak performance is required.
-
Q:
What are Micropipette Positive Control samples used for?
A:They are used for system suitability testing, method development, method comparison, method transfer, equipment qualification, and package process assessment.
-
Q:
What is a Micropipette Positive Control?
A:A Micropipette Positive Control is a pharmaceutical package sample with a precision-bored capillary glass tube sealed inside the container. It is used to simulate a defined leak path for CCIT validation and routine system checks.
-
Q:
Are traceable calibration certificates available?
A:Yes. Zholion Laser Drilling Positive Control samples can be supplied with traceable calibration certificates to support validation records and quality documentation.
-
Q:
What container types can be customized?
A:Zholion can provide CCIT Positive Control Samples for vials, ampoules, prefilled syringes, cartridges, IV bags, BFS containers, and other pharmaceutical packaging formats.
-
Q:
Can Laser Drilling Positive Control samples support USP <1207>?
A:Yes. Zholion Positive Controls for CCIT are designed to support pharmaceutical package integrity testing and help users build documentation aligned with USP <1207> expectations.
-
Q:
What are Laser-drilling Positive Control used for?
A:Laser Drilling of Pharmaceutical Packaging are used for CCIT method development, equipment qualification, routine system suitability testing, validation studies, and regulatory documentation.
-
Q:
What is a Laser Drilling Positive Control?
A:A Laser Drilling Positive Control is a pharmaceutical package sample with a precisely created micro-hole. It is used as a known defect sample to verify the sensitivity and reliability of leak test methods.
-
Q:
Why do regulatory agencies preferentially recommend deterministic test methods?
A:Regulators and pharmacopoeias preferentially recommend deterministic methods for several key advantages:
- Higher sensitivity and accuracy – can detect very small leaks relevant to product risk.
- Non‑destructive – tested samples can be released and sold (ideal for batch release and high‑value products).
- Objective, quantifiable data – supports trend analysis, statistical process control, and data integrity requirements.
- Automation and high throughput – suitable for online or at‑line QC in modern pharmaceutical manufacturing.
- While probabilistic methods retain value in certain validation contexts, deterministic methods are now the mainstream, scientifically preferred technology for CCI.
-
Q:
How do you validate the sensitivity of a CCI test method?
A:Validating sensitivity centers on using “known‑defect positive controls” to demonstrate that the method reliably and consistently detects target leaks.
Steps include:
1. Prepare positive controls with various leak sizes (covering small to large), using laser drillings, micropipettes, or realistically defective containers (e.g., micro‑cracked vials).
2. Test these positive controls and known‑intact negative controls multiple times using the candidate method.
3. Analyze results to identify the smallest leak size that is 100% detected (and 100% of negatives pass). This is the method's practical detection limit.
The validated detection limit must be equal to or better than the sensitivity of a microbial ingress challenge method for the method to be considered fully qualified.
-
Q:
What is the difference between probabilistic and deterministic test methods?
A:Probabilistic and deterministic methods differ fundamentally in principle, output, and reliability.
- Probabilistic methods (e.g., microbial ingress, dye ingress) – Results are influenced by variable factors. Output is typically qualitative or semi‑quantitative, and cannot precisely locate or size leaks. They provide probability‑based, indirect evidence of integrity.
- Deterministic methods (e.g., vacuum decay, laser-based headspace analysis) – Based on physical principles, measuring quantifiable parameters to directly detect leaks. Results are objective, quantitative, and highly repeatable, enabling calibration, trend analysis, and statistical process control. They provide a higher level of assurance and reliability. -
Q:
What is Container Closure Integrity (CCI)?
A:Container Closure Integrity (CCI) refers to the ability of a packaging system to prevent product loss, microbial ingress, and entry of gases (oxygen, air, water vapor, etc.) or other substances, thereby ensuring that the drug product remains safe and meets quality standards throughout its shelf life.
For injectable packaging systems, CCI requirements fall into three categories:
1. maintain sterility and product composition without the need to preserve headspace gas;
2. maintain sterility, product composition, and headspace gas;
3. for multi-dose containers that must maintain sterility after opening – prevent microbial ingress and product leakage during use. CCI studies for injectable products should be tailored to product characteristics.
A packaging system is generally considered to have acceptable CCI when it has passed or is capable of passing a microbial challenge test. In a broader sense, CCI means the absence of any leakage that could compromise drug quality. Based on scientific research and risk assessment, the Maximum Allowable Leakage Limit (MALL) should be determined considering packaging composition and assembly, product contents, and the environment to which the product may be exposed over its lifecycle. If a package’s leakage does not exceed its MALL, the closure system is considered integral.
-
Q:
Which regulations and guidelines address Container Closure Integrity?
A:Key regulatory and technical guidance documents for CCI include:
- EU GMP Annex 1 – Mandates container closure integrity verification and testing for terminally sterilized products, with differentiated requirements based on container type.
- USP <1207> – A comprehensive technical guide widely accepted as the industry standard, systematically describing test method categories, selection, validation, and lifecycle application. FDA guidance also permits physical CCI testing as an alternative to some sterility tests in stability studies.
- China NMPA – "Technical Guideline for Packaging System Integrity Study of Chemical Injectables (Trial)" – Signals increasing regulatory attention and alignment with international standards.
